Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis

Abstract Background The BOLT study for sonidegib, a Hedgehog pathway inhibitor (HHI) approved for patients with locally advanced basal cell carcinoma (laBCC) not amenable to curative surgery or radiotherapy, used modified Response Evaluation Criteria in Solid Tumors (mRECIST) for laBCC tumor evaluat...

Full description

Saved in:
Bibliographic Details
Main Authors: Ralf Gutzmer, Caroline Robert, Carmen Loquai, Dirk Schadendorf, Nicholas Squittieri, Ramon Arntz, Serena Martelli, Reinhard Dummer
Format: article
Language:EN
Published: BMC 2021
Subjects:
Online Access:https://doaj.org/article/9318906b3570461fb547c379286e05d0
Tags: Add Tag
No Tags, Be the first to tag this record!